FDA lifts hold on IND for CRISPR's sickle cell trial

CRISPR Therapeutics AG (NASDAQ:CRSP) and partner Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said late Wednesday

Read the full 137 word article

User Sign In